Organon and Shanghai Genomics collaborate on new research project
Organon, the human healthcare business of Akzo Nobel, and Shanghai Genomics Inc announced an agreement to collaborate on a new research project. The collaboration, which will involve biological development work aimed at progressing Organon's program for the identification of more selective steroid hormone receptor modulators, will initially last for a period of two years.
Shanghai Genomics, which in 2005 merged with GNI Ltd., the Asia-based global pharmaceutical company, will use its expertise in protein purification and cell-based interaction assays to clarify the clinical relevance of a number of receptor interacting proteins and their use in drug discovery. In particular, the research will focus upon the areas of rheumatoid arthritis, atherosclerosis and oncology.
Other news from the department business & finance
